secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001140361-24-035799
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres sells VOWST to Nestlé Health Science for $175M upfront plus milestones
----------------------------------------------------------------------------

- Seres to receive $175M at closing: $100M upfront (less ~$20M net settlement), $60M prepaid milestone, $15M equity at $1.05/share.
- Additional $75M due in 2025 subject to transition obligations; up to $275M in future commercial milestones on VOWST net sales.
- Seres to fully retire its senior secured debt with Oaktree at closing; expects cash runway into Q4 2025.
- Workforce to be reduced by more than one-third as VOWST capabilities transfer to Nestlé.
- Pipeline focus shifts to SER-155; Phase 1b placebo-controlled Cohort 2 data expected September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000114036124035799/0001140361-24-035799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000114036124035799/ny20030749x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-035799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer